

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATE/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

414 Rec'd PCT/PTO 10 OCT 2000

ATTORNEY'S DOCKET NUMBER:
VNN/KH/JJ/WCM64/USAU.S. APPL. NO. (if known, see 37 CFR 1.5)
09/673032INTERNATIONAL APPLICATION NO.:
PCT/GB99/01085INTERNATIONAL FILING DATE:
08 April 1999 (08.04.99)PRIORITY DATE CLAIMED:
09 April 1998 (09.04.98)

TITLE OF INVENTION: MODIFIED BIOLOGICAL MATERIAL

APPLICANT(S) FOR DO/EO/US: Bryan Paul MORGAN, Neil Kevin RUSHMERE, Stewart James HINCHLIFFE, and
Carmen Wilma VAN DEN BERG

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau. (see attached copy of PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Item 11. to 16. below concern document(s) or information included:
11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A **FIRST** preliminary amendment.
 - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 14. ☐ A substitute specification.
 15. ☐ A change of power of attorney and/or address letter.
 16. ☒ Other items or information: International Published Application (without International Search Report)
International Published Application (with International Search Report—only)
International Preliminary Examination Report (PCT/IPEA/409), International Search Report (PCT/ISA/210), Data Entry Sheet

APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold; margin-top: 5px;">09/673032</div>	INTERNATIONAL APPLICATION NO. PCT/GB99/01085	ATTORNEY'S DOCKET NO. WN/KH/JJ/JWCM64/USA												
CALCULATIONS PTO USE ONLY														
17. <input checked="" type="checkbox"/> The following fees are submitted:														
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1,000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00														
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00												
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00												
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> <tr> <td>Total claims</td> <td>33 - 20 =</td> <td>13</td> <td>X \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>9 - 3 =</td> <td>6</td> <td>X \$80.00</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	33 - 20 =	13	X \$18.00	Independent claims	9 - 3 =	6	X \$80.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE											
Total claims	33 - 20 =	13	X \$18.00											
Independent claims	9 - 3 =	6	X \$80.00											
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)		+ \$260.00												
TOTAL OF ABOVE CALCULATIONS =		\$ 1704.00												
Reduction of ½ for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		+ \$												
SUBTOTAL =		\$ 1704.00												
Processing fee of \$130 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.49(f)).		\$												
TOTAL NATIONAL FEE =		\$ 1704.00												
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$												
TOTAL FEES ENCLOSED =		\$ 1704.00												
Amount to be refunded:		charged:												
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1704</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 25-0120 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 25-0120 . A duplicate copy of this sheet is enclosed.														
SEND ALL CORRESPONDENCE TO YOUNG & THOMPSON 745 South 23rd Street 2nd Floor Arlington, VA 22202 (703) 521-2297 facsimile (703) 685-0573														
October 10, 2000		By <u>Benoit Castel</u> Benoit Castel Attorney for Applicant Registration No. 35,041												

09/673032

422 Rec'd PCT/PTO 1 0 OCT 2000 PATENTS :

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Bryan MORGAN et al.

Box Non-fee Amendment

Serial No. (unknown)

GROUP

Filed herewith

Examiner

MODIFIED BIOLOGICAL MATERIAL

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the first Official Action and calculation of the filing fee, please amend the above-identified application as follows:

IN THE CLAIMS:

Claim 3, line 1, cancel "or Claim 2".

Claim 5, line 1, cancel "or Claim 2".

Claim 6, line 1, cancel "or Claim 2".

Claim 7, lines 1 and 2, change "any of the preceding claims" to --claim 1--.

Claim 9, lines 1 and 2, change "any of Claims 1 to 8" to --claim 1--.

Claim 10, lines 1 and 2, change "any of Claims 1 to 8" to --claim 1--.

Claim 11, lines 1 and 2, change "any of the preceding Claims" to --claim 1--.

Claim 19, lines 2 and 3, cancel "or Claim 18".

Bryan MORGAN et al.

Claim 20, line 2, change "any one of Claims 17 or 19" to --claim 17--.

Claim 21, lines 3 and 4, change "Claims 17 or 19" to --claim 17--.

Claim 23, line 4, cancel "or 19".

Claim 26, line 2, change "any of Claims 17 and 19" to --claim 17--.

Claim 28, lines 1 to 3, cancel "or a nucleic acid sequence according to either Claim 17 or Claim 18".

Claim 29, line 2, cancel "or Claim 18".

Claim 32, lines 1, change "32" to --31--.

Respectfully submitted,

YOUNG & THOMPSON

By



Benoit Castel
Attorney for Applicant
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
703/521-2297

October 10, 2000

Modified Biological Material

This invention relates to modified biological materials and their use in transplants and also to associated methods. In particular, but not exclusively, the invention relates to the enhanced expression of endogenous complement regulatory molecules as a strategy for protection of xenotransplants.

Host cells are protected from their own complement by membrane-bound complement regulatory proteins. In humans, decay-accelerating factor (DAF or CD55), membrane cofactor protein (MCP or CD46) and CD59 perform this function. When an organ is transplanted into another species, natural antibodies in the recipient bind the endothelium of the donor organ and activate complement, thereby initiating rapid rejection. The hyperacute rejection caused by preformed antibodies and complement is a major barrier to the transplantation of pig organs to humans. It has previously been suggested that, in contrast to human cells, those of the pig are very susceptible to human complement, and it was thought that this was because pig cell-surface complement regulatory proteins are ineffective against human complement. When an organ is transplanted into another species, natural antibodies in the recipient bind the endothelium of the donor organ and activate complement, thereby initiating rapid rejection. In pig-to-primate transplants, most of the natural antibodies are IgM antibodies against the α -galactosyl epitope, which is expressed on pig endothelium but is absent in humans and

primates. Several strategies have been shown to prevent or delay rejection, including removal of IgM natural antibodies and systemic decompementation or inhibition of complement using sCR1, heparin or C1 inhibitor.

5 An alternative approach to the problem of hyperacute rejection is to express human, membrane-bound, complement-regulatory molecules in transgenic pigs. Transgenic pigs expressing DAF, MCP and CD59 have been generated, and these human inhibitors have been shown to be abundantly expressed
10 on porcine vascular endothelium. *Ex vivo* perfusion of hearts from control animals with human blood caused complement-mediated destruction of the organ within minutes, whereas hearts obtained from transgenic animals were refractory to complement and survived for hours.

15 The rationale for expressing human complement regulatory proteins in pig organs to "humanise" them as outlined above is based on the assumption that endogenous pig regulatory proteins are inefficient at inhibiting human complement and thus will contribute little to organ survival
20 in the context of xenotransplantation. Indeed, pig organs hyper-expressing human complement regulatory protein are much less susceptible to complement damage when perfused with human serum. However, it is our belief, based on experimental evidence, that the above assumption is
25 incorrect.

It has been suggested that hyperacute rejection of xenotransplanted organs might be inhibited by hyperexpression of either pig or human CD59 in the organ

(see van den Berg & Morgan, J. Immuno., 152, 4095-4101 (1994)). However, until the present invention hyperexpression of pig CD59 was not possible. Even with the cloning of pig CD59 now available as presented here, it could not be predicted that any expressed protein would function to inhibit human complement in nucleated porcine cells.

We have isolated and characterised the porcine analogues of several of the human complement regulatory proteins (CRP).

Porcine CD59 purified from pig erythrocytes inhibits human complement efficiently. We have cloned this molecule and shown that porcine CD59 expressed in a variety of cells is able efficiently to inhibit human complement.

Porcine MCP was purified from pig erythrocytes and has also been shown to inhibit human complement. We have recently demonstrated that neither of these porcine CRPs are species selective, and each inhibits both human and porcine complement to a similar degree.

We have also characterised another pig complement regulatory protein, porcine decay accelerating factor (DAF). This molecule has also been cloned and sequenced

Our studies indicate that pig organs expressing human complement regulatory protein molecules are resistant to complement damage not because they express human CRP molecules, but because they express greatly increased amounts of functional CRP molecules. We have found unexpectedly that increased expression of porcine CRP can be

equally effective in protecting the donor organ from complement damage leading to hyperacute rejection as donor organs expressing human complement regulatory proteins.

Thus the invention is based on the concept of manipulating endogenous CRP and other complement control mechanisms in porcine cells to generate organs, tissue and cells resistant to complement attack and hence to hyperacute rejection when transplanted into humans.

References herein to increased expression, hyper-expression, upregulated expression, etc., are used to mean that the cells are caused to express supra-physiological quantities of complement regulatory molecules. Although the extent of hyper-expression has not yet been fully established, our initial studies suggest that it should be several times that of the normal physiological level of expression, and possibly up to 10 times.

Summary of the Invention

In one aspect, this invention provides a graftable animal cell or tissue of a donor species for use in medicine, wherein said cell or tissue expresses, or is capable of being caused to express, increased amounts of endogenous complement regulatory molecules for preventing activation of complement in a recipient species.

The cell or tissue is preferably for use in transplantation therapy, and may be an organ e.g. a heart, lung, liver, kidney, pancreas, or thyroid. The cells may be isolated cells, e.g. islet cells, neurones, stem cells. The

tissue may be skin.

Preferably said complement regulatory molecules comprise complement regulatory proteins (CRPs).

The CRPs may comprise or have the activity of one or
5 more, of CD59, Membrane Cofactor Protein (MCP; CD46), Decay Accelerating Factor (DAF; CD55); complement receptor 1 (CR1; CD35), homologous restriction factor (HRF).

The donor species may be any suitable species for harvesting the particular organ tissue required, given size
10 etc. Thus, the donor species may be a pig or a sheep, or other species where appropriate. Likewise the recipient may be any suitable species requiring xenotransplantation, for example human.

In another aspect, this invention provides the use of
15 an animal cell or tissue derived from a donor species, wherein one or more complement regulatory molecules endogenous to the donor species can be hyper-expressed to prevent complete activation of complement in a recipient species, in the preparation of tissue graftable into the
20 recipient species without hyperacute rejection.

The invention also extends to a method of preparing an animal cell or tissue derived from a donor species for transplanting into a recipient species, and/or for reducing likelihood of hyperacute rejection once transplanted, which
25 comprises causing said cell or tissue to express increased amounts of one or more endogenous complement regulatory molecules sufficient to prevent activation of complement in the recipient species.

Thus, for example the cell or tissue may be transfected with a viral vector encoding a complement regulatory molecule.

Alternatively, the method may comprise the use of
5 cytokines or other factors acting directly or indirectly on regulatory elements in the CRP gene to increase expression of said CRP, before during or after transplant.

Cytokines are soluble proteins or glycoproteins produced by leukocytes and in some cases other cell types
10 which act as chemical communicators between cells. Cytokines bind specific receptors on the surface of target cells which are coupled to intracellular signalling pathways. Preferred candidates for upregulation of CRP or other complement defence mechanisms on endothelia are the
15 inflammatory cytokines tumor necrosis factor α (TNF α), interleukin- 1β (IL- 1β) and interferon- γ (IFN- γ). In the human, receptors for each of these cytokines are present on endothelia and each has been shown to increase adhesion molecule expression on endothelia. These molecules often
20 work well across species barriers (that is, human cytokines will bind and activate cells from other species). Often, mixtures of several different cytokines have a much greater effect than the sum of the individual cytokines in activating target cells, and the invention extends to use of
25 a combination thereof.

Chemokines are members of the cytokine superfamily distinguished by their ability to cause directed chemotaxis in some target cells. Receptors for several of these

molecules and related chemoattractants such as the complement fragments C5a and C3a are known to be expressed on endothelia. The term cytokine is used broadly to include chemokines.

- 5 The invention also extends to a transgenic animal having cells or tissue which hyper-express endogenous complement regulatory proteins. It is preferred to provide a clone.

- 10 In yet another aspect of this invention, there is provided a method of increasing the resistance of an animal cell or tissue of a donor species to complement attack when transplanted into a recipient species, which comprises:
- (a) exposing said cell or tissue to sub-lytic complement attack, or
 - 15 (b) exposing the cell or tissue to nutrient deprivation or
 - (c) applying conditions of limited anoxia to the cell or tissue, or (d) exposing said cell or tissue to ionophores, or (e) exposing said cell or tissue exogenous chemicals such as lectins thereby to increase the resistance of said cell
 - 20 or tissue to complement attack.

- Referring now to particular complement regulatory proteins, CD59 has been identified as an 18000-20000 MW glycosyl-phosphatidylinositol (GPI)-anchored protein that is a potent inhibitor of Complement attack during the formation
- 25 of the membrane attack complex of complement (MAC). CD59 binds to C8 in the forming MAC, and limits incorporation of C9, thereby preventing the formation of a lytic lesion. Nucleated cells can also escape Complement killing by

shedding vesicles enriched in the MAC and CD59. These recovery events are accompanied by increases in intracellular calcium concentration and other activation events, the triggers for which remain uncertain. Cross-linking of CD59 using monoclonal antibody (mAb) induces a cascade of events in nucleated cells that mimics non-lethal Complement attack and it has been proposed that non-lethal Complement attack may induce cell activation through interaction of CD59 with its natural ligand, the MAC. Therefore up-regulation of the Complement regulatory molecule CD59 during non-lethal Complement attack may be an important factor in rendering the cells less susceptible to subsequent Complement attack.

Analogues of human CD59 have been isolated by preparative SDS-PAGE; in particular, with respect to pig CD59, as described in J. Immunol. Meth. 179, 223-31 (1995). This method is based on the fractionation of a butanol extract of erythrocyte ghosts by preparative SDS-PAGE followed by gel filtration on Superose 12. Purification was monitored using a functional complement inhibition assay. SDS-PAGE analysis of the product of this procedure indicated a single protein band with apparent M_r of 20 kDa under reducing and non-reducing conditions. The preparation could be incorporated into guinea pig E to inhibit both cobra venom factor-reactive lysis and lysis through C8 and C9 using preformed C5b-7 sites, demonstrating that it contained a CD59-like activity.

Despite the multi-stage purification procedure and

apparent single band on SDS-PAGE, sequencing revealed two distinct signals at most cycles. Subtraction of the known sequence of the glycophorin fragment identified as a contaminant at the early stages of the preparation, beginning at residue 54 of the already published glycophorin sequence enabled the amino-terminal sequence of pig CD59 to be deduced. Repetitive yield plots for the two sequences were linear, providing good evidence for correct assignments. The amino acid terminal sequence published for the pig CD59 is given in SEQ ID NO:1 in which amino acid residues which were tentatively assigned as conserved cysteine or asparagine are shown in lower case.

We have now determined a full cDNA sequence for the pig CD59, cloned the molecule and also determined the functional characteristics of the expressed molecule.

Accordingly, in another aspect, this invention provides a DNA molecule selected from:-

- (a) a pig CD59 gene or its complementary strand;
- (b) a sequence substantially homologous to, or capable of hybridising to, a substantial portion of the gene defined in (a) above;
- (c) a mRNA coding for a polypeptide having an amino acid sequence defined in Figure 2 (SEQ ID No. 2);
- (d) genomic DNA corresponding to a molecule in (a) above,

and

(e) a fragment of a molecule defined in any of (a), (b), (c), or (d) above, other than the fragment identified in SEQ ID No.1.

5 Since the pig CD59 gene encodes a protein called pCD59, the pig CD59 gene therefore includes the DNA sequence shown in Figure 2 (SEQ ID No. 2), and all functional equivalents. The gene furthermore includes regulatory regions which control the expression of the pig CD59 coding sequence, including promoter, enhancer and terminator regions. Other
10 DNA sequences such as introns spliced from the end-product pig CD59 RNA transcript are also encompassed.

Using probes prepared as a result of sequencing the amino terminal sequence of pig DAF, it has been possible to
15 construct a pig testis cDNA library and subsequently to isolate clones encoding partial and full length pig DAF cDNA and thereafter to sequence pig DAF.

According to yet another aspect this invention provides DNA molecule selected from:-

- 20 (a) a pig DAF gene or its complementary strand;
(b) a sequence substantially homologous to or capable of hybridising to, a substantial portion of a molecule defined in (a) above;
(c) a molecule coding for a polypeptide having the sequence
25 of Figure 15 (SEQ. ID. Nos 17-19);
(d) genomic DNA corresponding to a molecule in (a) above;
and;

(e) a fragment of a molecule defined in any of (a), (b), (c), or (d) above

The invention also extends to RNA molecules comprising an RNA sequence corresponding to any of the DNA sequences set out above.

In another aspect, the invention provides a nucleic acid probe having a sequence as set out above; in particular, this invention extends to a purified nucleic acid probe which hybridises to at least a portion of the DNA or RNA molecule of any of the preceding sequences. Preferably, the probe includes a suitable label such as a chemiluminescent label or a radiolabel.

One or more of the DNA molecules defined above may be incorporated in a recombinant cloning vector for expressing a protein(s) having the amino acid sequence of Figure 2 and/or Figure 15, or a protein or a polypeptide having at least one functional domain or active site in common with said protein.

In another aspect, the invention provides a polypeptide encoded by a sequence as set out above, or having the amino acid sequence according to the amino acid sequence of Figure 2 (SEQ ID No. 2) or Figure 15 (SEQ ID No. 15), a protein or polypeptide having homologous properties with said protein, or having at least one functional domain or active site in common with said protein.

In particular, there is provided an isolated, purified or recombinant polypeptide comprising a pCD59 protein or a pDAF protein or a mutant or variant thereof or encoded by a

sequence set out above or a variant thereof having substantially the same activity as the pig CD59 protein or pig DAF protein.

The invention also extends to an anti-pig CD59
5 monoclonal antibody and to anti-pig DAF monoclonal antibodies. We describe herein two such antibodies identified as MEL-1 and MEL-2 respectively.

Preferably the monoclonal antibodies have an associated
10 label for use in observing, monitoring, purifying or localising pig CD59 or pig DAF in a sample.

List of Figures

The present invention will now be further described with reference to the accompanying figures, in which:

Figure 1 is a schematic diagram of the pig CD59 cDNA to
15 show the position of primers used in degenerate PCR, 3' RACE, 5' RACE and in cloning the full length coding region. These primer positions are shown in relation to the 5'-untranslated region (5' UTR), signal peptide, mature protein coding region, GPI-addition signal and 3'-untranslated region (3'-
20 UTR).

Figure 2 is the nucleotide and deduced amino acid sequence
of pig CD59 (SEQ ID NO:2). The numbers below refer to the nucleotide sequence, the numbers on
25 the right refer to the amino acid sequence. The first residue of the mature protein (L-1) is

boxed. Potential N-glycosylation sites (N-X-S/T) are denoted by psi (Ψ). The arrow (\downarrow) indicates the putative GPI-anchor addition site (S-73). The pig CD59 GenBank accession number is AF020302.

5 Figure 3 is the result of Northern blot analysis showing the relative expression of pig CD59 transcripts in different tissues detected using a cDNA radiolabelled probe derived from the coding region. A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was used as a control for loading of RNA between lanes. The lane marked "mRNA" contains mRNA isolated from cultured porcine endothelial cells. The positions of the major 1.3kb and 1.8kb transcripts are arrowed.

10
15 Figure 4 is a comparison of pig CD59 protein sequence with that of human, rat and mouse CD59. Numbering refers to the predicted pig CD59 sequence, with the first residue of the mature protein known from protein sequencing to be L. Vertical lines (|) show identity of conserved residues between pig CD59 and other species.

20
25 Figure 5 represents expression of pig (A) and human (B) CD59 in the U937 cell line and effect of phosphatidylinositol-specific phospholipase C (PIPLC) treatment. Transfected U937 cells were incubated for 30 minutes at 37°C with or without

PIPLC (0.4U/ml). Appropriate cells were then stained with MEL-2 (anti-pig CD59) or BRIC229 (anti-human CD59) and analysed by flow cytometry. --- binding of antibody to vector control cells; — (shaded), expression of CD59; — (non-shaded), PIPLC treated.

Figure 6 shows the result of a Western blot of pig CD59 expressing U937 cells, vector transfected U937 cells and pig red blood cells (PRBC) run under non-reducing (NR) or reducing (Red) conditions using MEL-1 anti-pig CD59. Molecular weight markers are shown on the left. Identical results were obtained using a second anti-pig CD59 mAb (MEL2IgG1). Control blots with isotype-matched Ab showed no binding.

Figure 7 relates to the classical pathway of complement mediated killing of U937 transfectants. Calcein-AM loaded cells were antibody sensitised and placed in 96-well plates. Cells were then incubated with varying dilutions of serum from several species. The species source is indicated in large letters at the top of each panel. Release of the fluorescent dye into the supernatant was measured on the WellFluor system and is expressed as a percentage of maximal release obtained after lysis of cells by

detergent.

●, Vector; ■, Human CD59; ▲, Pig CD59; ♦, Pig CD59 with blocking antibody. Points are means of triplicates determinations +/- SDs.

- 5 Figure 8 is a graph comparing the human complement lytic sensitivity of a pig endothelial cell line expressing pig CD59 or Human CD59;

Figure 9 is a Western blot comparing the time course of cofactor activity of pig MCP and human sMCP;

- 10 Figure 10 is a Western blot comparing the dose/response cofactor activity of pig MCP and human sMSP;

Figure 11 is a graph comparing the relative effectiveness of human sMCP and pig MCP as inhibitors of haemolysis by human serum;

- 15 Figure 12 is an SDS - PAGE gel of pig DAF illustrating presence of pig DAF with molecular weight of approximately 65 kDa. M = molecular weight markers; W = salt wash from column and e = column eluate with DAF band arrowed.

- 20 Figure 13 is a graph illustrating the inhibition of lysis in guinea pig erythrocytes incorporating pig DAF.

Figure 14 shows the nucleotide sequence of two different clones of pig DAF, i.e. pDAF-7 and pDAF-14 (SEQ ID Nos 15 and 16)

5 Figure 15 shows the predicted protein sequence of pig DAF .
from the nucleotide sequences of clones pDAF-7 and
pDAF-14 in Figure 14. It also shows the alignment
of the predicted protein sequence of clone pDAF-7
in alignment with the protein sequence of human
DAF (SEQ ID Nos 17,18 and 19)

10 Figure 16 is the result of Northern blot analysis showing
the relative expression of pig DAF in different
tissues detected using a cDNA probe derived from
the pDAF sequence given in Figure 14.

15 Figure 17 shows the activity of a pig DAF-Fc fusion protein,
purified from supernatants of transfected CHO
cells by protein A chromatography, to inhibit pig
and human complement. a) Fixed dose of DAF-Fc,
varying serum concentration; b) Fixed amount of
serum, varying dose of DAF-Fc.

20 Figure 18 contains two graphs showing the effect on
complement susceptibility (a) and expression of
CD59 and MCP (b) in primary pig aortic endothelial
cells (PAEC) when treated with phorbol myristate
acetate (PMA)

Figures 19a

and 19b show the effect of exposure to non-lethal complement attack on the resistance to complement lysis of PAEC (a) or on the expression of CD59 and MCP (b) by the cells

Figure 20 shows the effect of anoxia on (a) susceptibility to complement lysis, and (b) expression of CD59 and MCP on PAEC

Figures 21a

and 21b show the effect of growth arrest induced by nutrient deprivation or cell density on the resistance to complement lysis of human erythroleukaemia cell line K562 and on the expression of CD59 and MCP by the cells.

Figure 22 shows the expression of pig CD59 on PAEC at different passages.

Figure 23 shows the expression of pig CD59 on PAEC at different passages.

Figure 24 shows the complement susceptibility of PAEC at different passages.

Figure 25 shows the effect of blocking CD59 and MCP of C-susceptibility of PAEC.

Figure 26 shows the effect of incorporation of human CD59 into PAEC and the effect of blocking of human and pig CD59 on complement susceptibility.

The initial portion of pig CD59 cDNA sequence was
5 obtained by touchdown polymerase chain reaction (PCR) using
two degenerate primers, the first designed from a region in
the 38 amino acids of N-terminal sequence previously
obtained, as mentioned above, the second designed based upon
a region of high homology between human, rat and mouse CD59
10 near the C-terminus of the mature protein. The precise
sequence of this latter region in pig CD59 was not known so
the degeneracy of this primer was high to allow for many
combinations. Once this internal stretch of sequence had
been determined, gene specific primers were designed to
15 complete the sequencing using the Rapid Amplification of
cDNA Ends (RACE) approach. The 5' RACE reactions yielded a
single specific product, while the 3' RACE reactions yielded
four specific products. Two of these were sequenced and
shown to be identical apart from the length of the 3' UTR;
20 the two longer products were not sequenced but were likely
also to be pig CD59 mRNA transcripts with longer 3' UTR. The
suggestion that there are several different length
transcripts of pig CD59 mRNA is supported by the Northern
blots which show multiple specific bands of 0.8kb, 1.3kb,
25 1.8kb and 3.0kb (Figure 3). This is similar to the
situation for human CD59, which has five different length
transcripts of 0.7kb, 1.3kb, 1.9kb, 2.1kb and 5.8kb all due

to alternative polyadenylation. In contrast, only a single transcript of 1.8kb has been identified in rat CD59.

The full cDNA sequence (Figure 2) (SEQ ID No. 2) contains a 84bp 5' UTR, a 372bp coding region, and a 312bp 3' UTR. In the 5' UTR the 22bp immediately 5' to the ATG start site is highly homologous between human, rat and mouse CD59, but is not conserved in the pig CD59 sequence. The Kozak sequence ($A/GNNATG$), recognised by ribosomes as the translational start site and thus required for protein expression, is present within the pig CD59 5' UTR sequence. The coding region consists of a 26 amino acid NH_2 -signal peptide, with leucine known to be the first residue of the mature protein sequence from the above-mentioned amino acid sequence. Based on the consensus sequence for a phosphatidylinositol glycan anchor additional signal (GPI) (J. Biol. Chem. 267 12168) it is predicted that the COOH-terminal 25 amino acids will be cleaved off and a preformed GPI-anchor attached to the Ser-73. The resulting 73 amino acid mature protein is 48% identical to human CD59, 46.5% identical to rat CD59 and 38% identical to murine CD59 at the amino acid level. There are two potential N-glycosylation sites in the pig CD59 sequence, at Asn-18 and Asn-71. The former site has previously been shown by protein sequencing to be occupied; it is unlikely that the latter site is occupied due to its close proximity to the GPI-attachment site, and thus the membrane.

It has been demonstrated by structural analysis of human CD59, that in the mature protein, the 12 amino acids

at the C-terminus, following human residue Cys-64, have no defined structure and act like a "stalk", giving mobility to the molecule. The predicted GPI attachment site in pig CD59 is at Ser-73. The "stalk" of pig CD59 is thus only 7 amino acids in length, the same length as that of mouse CD59, but 5 amino acids shorter than that of human CD59, and 7 amino acids shorter than that of rat CD59. We have suggested that the short "stalk" of murine CD59 is responsible for the inefficient release of the molecule by PIPLC. Pig CD59 expressed on U937 is efficiently released by PIPLC treatment, although not to the same extent as human CD59 expressed on the same cell (Figure 5). This indicates that the length of "stalk" has relatively little effect on the accessibility of the GPI anchor to the PIPLC enzyme.

Pig CD59 was stably expressed in the CD59-negative human cell line U937. Western blotting showed that the expressed pig CD59 protein was of the predicted molecular weight and was glycosylated in a manner similar to that of human CD59 (Figure 6). In fresh pig erythrocyte membranes there is an additional form of CD59 of molecular weight 10kDa which may represent unglycosylated or deglycosylated CD59. Small amounts of deglycosylated CD59 have been observed on erythrocytes in other species, particularly after prolonged storage at 4°C. The abundance of this form on fresh pig erythrocytes suggests that the protein may be rather more susceptible to deglycosylation *in vivo* than CD59 in other species.

U937 cells stably expressing either pig or human CD59

showed a single homogeneous population of high expressors by flow cytometry using appropriate mAbs. This homogeneity of expression is mediated by the elongation factor 1 α promoter in the expression vector, which varies little in its expression levels. Pig CD59 and human CD59 in the same vector and in the same cell type were therefore expressed at similar levels on the cell surface and could be directly compared.

The expressed pig CD59 inhibited lysis by complement from a variety of species, as previously reported with CD59 purified from pig erythrocytes (van den Berg et al J. Immunol. 152 4095 (1994)). The pattern and extent of inhibition was almost identical to that obtained with human CD59 expressed in the same cell line. Both pig and human CD59 were very effective at inhibiting pig, human and sheep complement and less effective at inhibiting rodent complement (Figure 7). These data suggest that the residues involved in species selectivity are well conserved between human and pig CD59, but less so in rodent CD59s. In studies of human-rat CD59 chimaeras, the region of human CD59 between residues 40 and 66 has been implicated as conferring species selectivity between human and rat CD59. Within this region are several residues conserved between human CD59 and pig CD59, but not conserved in rat and mouse CD59. Residues Phe-47 and Lys-66 (human numbering) are conserved (Ala/Gly and Ala/Phe respectively in rat/mouse) and there are conservative substitutions at human residues 43 (Glu \rightarrow Asp), 51 (Thr \rightarrow Ser) and 65 (Lys \rightarrow Arg) (Ser/Ser, Leu/Met and Gln/Gln

respectively in rat/mouse). These residues may therefore be important in the species selectivity of CD59 molecules.

Expression of CD59 analogues at high levels in a CD-59-negative cell line provides a model for the situation in transgenic pigs developed for xenotransplantation, where human CD59 has been expressed at high levels in certain organs in order to inhibit the damage during complement attack by human serum. Pig CD59 and human CD59, expressed at high levels in the human U937 cell line, inhibit human complement to a similar extent, indicating that it is the level of expression rather than the species of CD59 which is important in conferring protection.

The above data indicate that hyper-expression of an endogenous CRP such as pig CD59 in the transplanted organ would provide protection equal to that conferred by hyper-expression of human CRP in the pig. Hyper-expression of the endogenous inhibitors could be achieved by transgenesis, but there may be alternative ways of achieving this end, for example, by identifying agents which cause a large, sustained upregulation of CD59 expression on donor endothelial cells.

The present invention will now be illustrated and specifically described in the following examples.

Examples

25 Materials and Methods used in the Examples

Materials

Molecular Biology. All general reagents were from Sigma Chemical Co. (Poole, UK) unless otherwise stated. Ultraspec RNA isolation media was from Biotecx (Houston, USA). Rnase H Superscript reverse transcriptase, Rnase H, terminal dioxynucleotide transferase and all restriction enzymes were from Life Technologies (Paisley, UK). NickTM columns for radioactive probe purification, Taq polymerase and buffers were from Pharmacia (Milton Keynes, UK); Vent DNA polymerase was from New England Biolabs (Veverly MA); and dNTPs were from Bioline (London, UK). RNase inhibitor rRnasin[®] and pGEM-T vector kit were from Promega (Southampton, UK). Geneclean II DNA purification kit was from Anachem (Luton, UK) and plasmid purification kits were from Qiagen (Dorking, UK). Hybond-N nylon membranes, Rapid-Hyb buffer, rediprime DNA labelling system and [α -³²P]dCTP were from Amersham International (Little Chalfont, UK). Oligonucleotide primers were synthesised in house on an ABI Model 394 synthesiser (Applied Biosystems, Warrington, UK).

Tissues, Cells and Sera. Animal sera were obtained fresh from the animal facility of the University of Wales College of Medicine and stored at -70°C. Normal human serum was obtained from healthy volunteers and stored at -70°C.

The human promonocyte U937 cell line was originally obtained from the European Collection of Animal Cell Cultures (ECACC, Porton Down, UK). The derivation of a CD59-negative subclone is described in Immunology 81 637 et seq. (1994). Cells were cultured in RPMI 1640 medium (Life Technologies), Paisley, UK) supplemented with 10% FCS, 4mM

glutamine, 2mM sodium pyruvate, 100 IU/ml penicillin, 100IU/ml streptomycin and 2.5µg/ml amphotericin. Pig endothelial cells isolated from pig aorta by standard methods were a kind gift from the Department of Cardiology, University of Wales College of Medicine. All tissues for Northern blots were obtained fresh from the local abattoir.

Antibodies. High titer polyclonal antiserum against CD59-negative U937 cells was raised in rabbits using standard procedures. The monoclonal antibodies to pig CD59 (MEL-1 and MEL-2) were generated in house, as described in detail below. BRIC229 (α-human CD59 mAb) was from International Blood Group Reference Laboratory (IBGRL, Bristol, UK). Goat anti-mouse/IgG-horseradish peroxidase (GoM-HRPO) was from Bio-Rad (Hemel Hempstead, UK). Goat anti-mouse/IgG-phycoerythrin (GoM-PE) was from DAKO (Denmark).

Monoclonal Antibody Production

Monoclonal antibodies to pig CD59 were made by standard protocols. (Galfre, G, Milstein, C, (1981) Preparation of Monoclonal Antibodies: strategies and procedures. Methods - Enzymol.73.3) Briefly, BALB/C mice were immunized subcutaneously with pig erythrocyte ghosts in Freund's Complete Adjuvant (FCA). Animals were boosted twice by intraperitoneal (i.p.) injection of highly purified pig CD59 prepared by preparative electrophoresis 3 weeks and 14 weeks later, with and without Freund's Incomplete Adjuvant (FIA) respectively. A third and final i.p. boost of pig

erythrocyte ghosts was administered 37 weeks after the initial immunization. Animals were sacrificed, spleens removed, spleen cells harvested and fused with the mouse myeloma cell line SP2/0 9 days after the final boost.

5 Positive clones were selected by incubation of hybridoma supernatants from individual wells with U937 cells expressing or not expressing pig CD59 followed by determination of bound antibody by flow cytometry, and by Western blotting using cell lysates of the U937 transfected

10 cells. Three separate positive wells were taken through secondary and tertiary cloning and then grown in bulk. Three monoclonal antibodies were produced, one IgM (MEL-1) and two IgG1 (MEL-2 and MEL-3). Immunoglobulins were isotyped using the Isostrip Kit (Boehringer Mannheim,

15 Mannheim, Germany) or the Isotyping Kit (Sigma Chemical Co.) MEL-2 and MEL-3 were chosen for further studies and for purification purposes.

Purification of Immunoglobulins

The IgG's were purified using a protein A column

20 (Prosep A beads, Bioprocessing, Durham, UK). Protein concentration was determined using a Coomassie Blue Protein assay (Pierce, U.K.).

Reverse Transcription

Total RNA was extracted from cultured pig endothelial

25 cells using the Ultraspec RNA isolation system. The RNA was reverse transcribed by incubation with 500U Superscript

RNase H-Reverse transcriptase at 20°C for 10 minutes, then 42°C for 90 minutes in the presence of 50mM Tris-HCl, 75mMKCl, 3mM MgCl₂, 5μM DTT, 60U rRNasin® and 2mM dNTPs, in a total volume of 30μl.

5 PCR Amplifications

All PCR reactions were carried out in a OmniGene thermal cycler (Hybaid, Middlesex, UK). Taq DNA polymerase (2.5U) was used to amplify the DNA in the presence of NH₄⁺ buffer (16mM (NH₄)₂SO₄, 67mM Tris-HCl, 0.01% Tween-20), 1mM
10 MgCl₂, 0.08mM dNTPs and appropriate primers, in a total reaction volume of 50μl overlaid with mineral oil.

Degenerate PCR Amplification

Random hexamers of DNA (500ng) were used to prime the initial reverse transcription of 10μg total RNA to produce
15 a template for the PCR amplification.

Degenerate primers A-PIG (TG^C/_TTA^C/_TAA^C/_TTG^C/_TAT^A/_C/_TAA) (SEQ ID No. 3) and C-PIG (AG^G/_ATC^C/_TTC^C/_T^C/_TT^G/_T^G/_ACA^G/_ACA) (SEQ ID No. 4) were derived from amino-terminal protein sequence corresponding to residues 3-8 (CYNCIN) of pig CD59 and a
20 region of high inter-species homology of all known CD59 sequences close to the C-terminus corresponding to residues 63-68 (CCKKDL) in human CD59. The approximate positions of these primers are shown in the schematic diagram of the pig CD59 cDNA (Figure 1). A variation on the touchdown
25 procedure of Don et al Nucleic Acids Res. 19:4008 was performed, with 500ng of each primer used in the

amplification. A denaturation at 95°C for 4 minutes was followed by initial cycling parameters of 94°C for 30s, 54°C for 40s and 72°C for 45s. Thereafter the annealing temperature of the reaction was decreased 2°C every second cycle from 54°C to a touchdown of 40°C at which temperature 25 cycles were carried out.

Derivation of the 3' end of pig CD59 cDNA

The method used was a modification of the rapid amplification of cDNA (RACE) method described by Frohman, M.A. 1990 PCR Protocols: A Guide to Methods and Applications. Academic Press, London, pp 28-38). A poly-dT adaptor primer Q_T (CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCT₁₇) (SEQ ID No.5) (28pmol) was used to reverse transcribe mRNA from 10µg total RNA. Q_T binds to the poly-A tails of all mRNAs thus priming reverse transcription and consequently adding an extra 35 bases of unique sequence to the cDNA end. Nested PCR was performed using primers specific for this unique sequence, Q₀ (CCAGTGAGCAGAGTGACG) (SEQ ID No.6) and Q₁ (GAGGACTCGAGCTCAAGC) (SEQ ID No.7) along with pig CD59 specific primers D-PIG (TGCACTACGGCCATGAATTG) (SEQ ID No.8) and E-PIG (TCGTTGAAGCCGTGCCACCC) (SEQ ID No.9), designed from the cDNA sequence obtained from the degenerate primer PCR reaction. The positions of these primers are shown in Figure 1.

In the first amplification 7% of the Q_T primed cDNA was amplified using 25pmols of primer Q₀ and the degenerate primer A-PIG, using touchdown PCR as above. In the second

amplification a 1 μ l aliquot of a 1:20 dilution of the first reaction was amplified using 25pmol Q₁ and 25pmol D-PIG with the following reaction conditions: 94°C for 30s, 54°C for 1 minute (ramp 2.5) and 72°C for 2 minutes for 30 cycles. In the third amplification a 1 μ l of a 1:20 dilution of the second amplification was amplified using 25pmol Q₁ and 25pmol E-PIG with the following reaction conditions: 94°C for 30s, 58°C for 1 minute (ramp 2.5) and 72°C for 2 minutes for 30 cycles.

10 Derivation of the 5' end of pig CD59 cDNA

A pig CD59 specific primer RT-PIG (AGGTCCTTCTTG CAGCAGTG) (SEQ ID No.10) (6pmol), derived from the cDNA sequence obtained from the degenerate PCR reaction, was used in the reverse transcription of the 5' end of the mRNA from 10 μ g total RNA. After reverse transcription the RNA was degraded by incubation for 20 minutes at 37°C with 2.5U RNase H. The single stranded cDNA generated by reverse transcription was purified from primers and enzyme using the Geneclean II kit (Anachem). The purified cDNA was polyadenylated at its 3' end by incubation with 10U terminal deoxynucleotide transferase (Life Technologies) in the presence of 5mM ATP at 37°C for 5 minutes, then 65°C for 10 minutes. The mixture was heated to 95°C to denature the enzyme and 5% of the resulting polyadenylated single-stranded cDNA was used directly in the first PCR amplification. The poly-A tail generated was used to initially amplify the cDNA with the adaptor primer Q_T

followed by further amplification using the primers Q₀ and Q₁ and the pig CD59 specific primers G-PIG (CTTCTCCGCTAGGTTTCTCG) (SEQ ID No.11) and F-PIG (GCATTCATCGAACCTCCAAC) (SEQ ID No.12), which were designed from the cDNA sequence obtained from the degenerate PCR reaction.

In the first amplification the cDNA was amplified using 3pmol Q_T primer, 25pmol Q₀ and 25pmol G-PIG, using the following conditions: 96°C for five minutes, 50°C for 2 minutes (ramp 2.5) and 72°C for 40 minutes, followed by 30 cycles of 94°C for 1 minute, 58°C for 1 minute and 72°C for 2 minutes.

A 1μl aliquot of a 1:20 dilution of the first reaction was reamplified using 25pmols of each of the nested primers Q₁ and F-PIG using the following conditions: 94°C for 1 minute, 58°C for 1 minute (ramp 2.5) and 72°C for 2 minutes for 30 cycles.

Cloning and Sequencing of PCR Products

Purified PCR products were ligated into the pGEM-T vector cloning site (insert:vector molar ratio 3:1) by incubation with 1 Weiss Unit of T4 DNA ligase (16°C for 16 hours) in a total volume of 10μl of 30mM Tris-HCl (pH 7.5), 10mM MgCl₂, 10mM DTT and 1mM ATP. A 1μl aliquot was then electroporated into electrocompetent DH5α *Escherichia coli* at 2.5kV, 25μFD and 200Ω using a Bio-Rad Genepulser. The bacteria were then grown on Luria-Bertani/Agar plates and selected for by ampicillin resistance and by blue/white

colour selection using X-Gal (5-bromo-4-chloro-3-indolyl β -D-galactoside) substrate. Positive colonies were picked, a portion retained for checking insert size and the remainder replated on LB/Agar plates. The retained portion was boiled
5 in 20 μ l water for 10 minutes to release and denature the plasmid, then put on ice for 10 minutes. PCR was performed using 5 μ l of boiled bacteria as the template and T7 and SP6 primers which flank the insert site in the vector, and the reaction resolved on agarose gels. Colonies with inserts of
10 the correct size were expanded for 16 hours in 5mls LB broth containing 50 μ g/ml ampicillin at 37°C and the plasmids purified using the QIAprep spin plasmid kit (Qiagen).

Automated sequencing was carried out in house using an ABI model 377 DNA sequencer. (Applied Biosystems,
15 Warrington, UK).

Southern and Northern Blot Analysis

Probes for Southern and Northern blot analysis were generated from double-stranded pig CD59 template DNA isolated by elution from a low melting point agarose gel.
20 The DNA concentration was measured and adjusted to 550ng/ml prior to denaturation at 95°C for 2 minutes and quenching in ice water. Lyophilised Redi-prime constituents were reconstituted in 45 μ l template DNA, 5 μ l (50 μ Ci) of [α -³²P]dCTP added and the mixture incubated at 37°C for 1
25 hour. The product was purified from remaining nucleotide using a Nick column (Pharmacia, Milton Keynes, UK) and stored at 4°C.

Total RNA for Northern blot analysis was purified from whole tissues and from cultured pig aortic endothelial cells using the Ultraspec RNA isolation system. The PolyAtract mRNA isolation system (Promega, Southampton, UK) was used to purify messenger RNA from cultured endothelial cells. Total RNA (10µg) or mRNA (2µg) was run on denaturing agarose gels and transferred overnight to Hybond,N nylon membrane using capillary action. For Southern blot analysis PCR products were run on agarose gels and transferred to Hybond-N using capillary action. The nucleic acids were crosslinked to the membrane by U.V. irradiation (U.V. Stratalinker, Stratagene UK). The membrane was prehybridised in Rapid-Hyb buffer at 65°C for 1 hour before addition of the radiolabelled probe which had been denatured at 95°C. Southern blots were hybridised with a 200bp probe generated from the pig CD59 cDNA cloned using degenerate primers. This was hybridised for 3 hours at 65°C, washed 2x5 minutes with 0.2xSSC/0.1%SDS at 65°C, and exposed to X-ray film for up to 6 hours at -70°C. Northern blots were hybridised for 16 hours at 65°C with a 610bp probe generated from the pig CD59 coding sequence cloned in the expression vector. This was washed at room temperature with a 2x10 minutes 2xSSC/0.1%SDS and 2x10 minutes 1xSSC/0.1%SDS, and exposed to X-ray film for up to 48 hours at -70°C.

25 Construction of eukaryotic expression vector for transfection of pig CD59

The eukaryotic expression vector pDR2EF1α was a gift

from Dr. I. Anegon (INSERM U437, Nantes, France) Transplantation 58:1222. PDR2EF1 α contains hygromycin resistance gene, allowing the selection of stable colonies, and the powerful polypeptide chain elongation factor 1 α promoter to generate high expression levels Nucleic Acids Res. 18:5322. From the full length pig CD59 sequence two primers, PIGXP-1 (GGTTCTAGAGTAGCGCTGCAGCCGGAC) (SEQ ID No.13) and PIGXP-2 (GGTGGATCCTTCTCTGCCAACAGGCCT) (SEQ ID No.14), were designed to PCR amplify the entire coding region, including the Kozak sequence, essential for ribosomal recognition of the translational start site. These primers contain Xba-1 and BamH1 restriction sites respectively. These sites are also present as unique sites in the insertion region of the expression vector, allowing correct orientation of the insert. PCR product and vector were restriction enzyme digested prior to ligation. The presence and fidelity of the pig CD59 in the vector was confirmed by DNA sequencing.

Transfection of CD59-negative U937 cell line

The promonocytic cell line U937 was transfected by electroporation with the empty expression vector, the expression vector containing pig CD59 or vector containing human CD59 J.Immunol. 158:1692. U937 cells growing in log phase were washed 3x with sterile PBS and resuspended in ice-cold RPOMI-1640 from Gibco at a final concentration of 3×10^7 cells/ml. Cells (450 μ l) were added to a sterile cuvette with 10 μ g of super coiled plasmid. The cuvette was

placed on ice for 5 minutes and electroporated at 270V and 960 μ F using the Bio-Rad Genepulser with capacitance extender. The cuvette was then placed on ice for a further 30 minutes. Cells were returned to sterile culture flasks and cultured for 24 hours in 10ml fresh RPMI containing 10%FCS. Cells were washed once in sterile 0.9% NaCl and resuspended in selection medium (RPMI containing 0.7mg/ml hygromycin B; Boehringer Mannheim, Lewes, UK). Selection medium was changed every two days for approximately 2 weeks, by which time all the non-transfected control cells had died. Transfected cells were then maintained in RPMI containing 0.1mg/ml hygromycin B.

FACSscan analysis

Cells were harvested, washed three times in PBS/1%BSA, and resuspended at 10^6 cells/ml in VBS (Veronal buffered saline)/1%BSA. All steps were conducted on ice. Cells (10^5) were incubated with appropriate mAbs at 10 μ g/ml for 30 minutes, washed three times with VBS/1%BSA, and incubated for 30 minutes with a 1/100 dilution of goat anti-mouse/IgG phycoerythrin. Cells were washed three times in VBS/1%BSA, and fluorescence was measured using a FACScalibur flow cytometer (Becton-Dickinson, San Jose, USA).

To examine the effects of treatment with phosphatidylinositol-specific phospholipase C (PIPLC), cells were washed and resuspended at 3×10^6 /ml in PBS containing PIPLC (0.4U/ml, Peninsula Laboratories, St. Helens, UK). After an incubation for 30 minutes, cells were washed and

CD59 expression measured by flow cytometry using the above protocol.

Functional assays

To eliminate the interfering effects of antibiotics, stably transfected cells were cultured in the absence of hygromycin B for seven days before assessment of sensitivity to complement lysis. Cells growing in log phase were harvested, washed three times in PBS, resuspended in RPMI/10%FCS at 10^7 cells/ml and loaded with calcein-AM (Molecular Probes, Oregon, US; $2\mu\text{g/ml}$) for 30 minutes at 37°C . Cells were washed twice with PBS and resuspended in a 1/5 dilution of heat-inactivated rabbit anti-U937 polyclonal antiserum in VBS/1%BSA for 15 minutes at 4°C . Cells were washed once in PBS and resuspended in VBS/1%BSA containing the appropriate dilution of fresh serum. The mixture was incubated for 30 minutes at 37°C , after which the cells were pelleted, the supernatant removed and retained for fluorescence measurement using the WellFluor system (Denley, Sussex, UK). The cells were then incubated for a further 15 minutes in 0.1% Triton X-100, to release any remaining calcein. Residual cell debris was pelleted and the supernatant removed for fluorescence measurement. Percentage lysis by serum was calculated as follows:

$$\% \text{ lysis} = \frac{\text{calcein released by complement} \times 100}{\text{calcein released by complement} + \text{calcein released by detergent}}$$

SDS-PAGE and Western blotting of cell lysates

Samples were run on 15% SDS-PAGE gels under non-reducing conditions, blotted onto nitrocellulose and blocked with 5% dried milk/PBS. The blots were incubated for 1 hour at room temperature with primary antibodies (10 μ g/ml in 5% dried milk/PBS), washed three times in PBS/0.1%Tween-20, incubated with goat anti-mouse/IgG horseradish peroxiase (1/1000 in 5% dried milk/PBS), and washed with PBS/0.1%Tween-20, and twice with PBS. Blots were developed using Supersignal Chemiluminescent Substrate (Pierce, Rockford, IL).

Example 1: PCR cloning of Pig CD59 cDNA

Degenerate PCR using primers A-PIG and C-PIG produced four PCR products, ranging in length from 150bp to 400bp. All the PCR products were cloned into the pGEM-T vector and electroporated into DH5 α bacteria. From the resultant colonies, 20 were screened by PCR using T7 and SP6 primer sites in the vector which identified 6 colonies containing an insert of the predicted length (200bp). These 6 colonies were grown up and the plasmids purified and sequenced. All were identical. The amino acid sequence derived from this cDNA sequence was 100% identical to the above-mentioned partial amino acid sequence for purified pig CD59, thus confirming that the sequence was correct.

This sequence was then used to design primers in order to PCR amplify the 3' and 5' ends (primers summarised in Figure 1). 5' RACE, using primers Q₀ with G-PIG, followed

by a second amplification using primers Q₁ with F-PIG, produced a strong 300bp PCR product which Southern blotted with a probe derived from the 200bp of known sequence. This was cloned, sequenced and confirmed to be the 5' end of the cdna. 3'RACE produced four PCR products of ~350bp, ~500bp, ~1kb and ~1.3kb, all of which hybridised on a Southern blot with the 200bp probe. The 350bp and 500bp products were cloned and sequenced, and were confirmed to contain the 3' end of pig CD59, differing only in the length of the 3' UTR.

5 The longer products were not analysed further, but were thought to be likely to represent yet longer transcripts of pig CD59.

10

Reverse transcriptase PCR of the full-length cdna for ligation into the expression vector produced a single 629-bp product. After ligation and electroporation, 12 clones were picked and the plasmids purified and sequenced of the 12 clones, 10 gave the identical sequence, the other two, differing by one or two bases.

15

The full length cdna sequence is shown in Figure 2.

20 The sequence encodes a 84bp 5' UTR, a 26 amino acid NH₂-signal peptide, and a 98 amino acid coding region including two putative N-glycosylation sites at N-18 and N-71 and a glycosyl phosphatidylinositol (GPI) anchoring signal. The predicted site of GPI anchor addition based upon the known requirements for anchor addition is at S-73. The mature protein sequence is 48% identical to human CD59, 46.5% identical to rat CD59, and 38% identical to murine CD59. A comparison of the sequences of the various CD59 analogues is

25

shown in Figure 4.

Example 2: Northern Blot Analysis

Northern blot analysis of mRNA from porcine endothelial cells indicated that pig CD59 had two major transcripts of 1.8kb and 1.3kb, which are clearly visible in Figure 3; two faint bands of 0.8kb and 3.0kb were consistently seen on a longer exposure. The 3' UTR of the longer of the sequenced clones was 312bp which correlates with the 0.8KbmRNA species, but Northern blot analysis demonstrates that mRNA species with even longer 3'UTR were also present.

Northern blot analysis was also performed on total RNA freshly extracted from pig tissues (Figure 3). Expression of pig CD59 was found in all tissues, albeit at different levels. Expression was highest in lung and spleen and was low in liver and skeletal muscle. The relative expression of the two major bands at 1.8kb and 1.3kb also varied between tissues, lung expressing similar amounts of the two, spleen rather more of the larger band while testis, cardiac and skeletal muscle expressed almost none of the lower band. Probing for GAPDH confirmed that similar amounts of RNA had been loaded for all tissues with the exception of lung where rather less RNA was loaded.

Example 3: Expression of Pig CD59 in a CD59-Negative Cell Line

Stable populations of U937 cells expressing pig or human CD59 were generated as discussed above. Expression

was confirmed using the mAb BRIC229 (IgG2b) for human CD59, and a new mAb raised against pig erythrocytes and conclusively shown to recognise pig CD59 (MEL-2 IgG1). Uniform, high level, stable expression was obtained for both
5 proteins (Figure 5). The pDRAEF1 α vector was chosen because it was reported to give comparable levels of expression of different cDNAs in a given cell type. It was therefore anticipated that similar levels of expression of human and pig CD59 would be achieved.

10 Neither of the mAbs recognized vector control cells, BRIC229 was negative on pig CD59-transfected cells. Although precise comparison of expression based upon staining with different reagents is not possible, the data suggest that pig CD59 and human CD59 were expressed at
15 similar levels. Expression of pig CD59 on transfected U937 cells was sixfold that of endogenous CD59 on the endothelial cell line PLECT, as assessed by flow cytometry (data not included). We have shown previously that expression of human CD59 on U937 cells using this vector was approximately
20 10-fold higher than levels obtained on cells endogenously expressing the protein (endothelial cells and K562 cell line).

Treatment of transfectants with PIPLC decreased expression of pig CD59 by 50%, as assessed from the mean
25 cell fluorescence of the population, confirming that the protein was GPI anchored (Figure 5a). This decrease in expression following PIPLC treatment is similar to that of human CD59 expressed on the same cell type, which decreased

in mean cell fluorescence by 65% (Figure 5b)

Western blotting of pig erythrocyte membranes using two different anti-pig CD59 mAb (MEL-1 IgM; MEL-2Ig1) revealed a broad band in the M_r range of 16 to 22 kDa, and a second
5 distinct band of 10kDa, whereas blotting of pig CD59-expressing U937 cell membranes revealed a ladder of bands in the M_r range of 17 to 23kDa (Figure 6). Western blots using isotype-matched controls for both Abs showed no reactivity with pig erythrocyte membranes, or pig CD59-expressing U937
10 cells. With the exception of the distinct band at 10 kDa in pig E, these patterns closely resemble those seen for CD59 from other species and represent variable glycosylation of the CD59 (1, 8-10). Preliminary data indicate that the 10-kDa erythrocyte band represents
15 unglycosylated/deglycosylated CD59. Neither Ab recognized pig CD59 following reduction, a characteristic common to all anti-CD59 Abs in all species examined. There was no cross-reactivity of the anti-pig CD59 mAbs with human CD59 or of any of the available anti-human CD59 Abs (a panel of 10)
20 with pig CD59 (data not included).

Example 4: Functional Activity of Pig CD59

The complement inhibitory activity of pig CD59 expressed on U937s was evaluated, and compared with that of expressed human CD59, using a calcein-AM dye release assay.
25 Transfectants expressing pig CD59, human CD59 or vector alone were antibody sensitised and incubated with sera from various species at different dilutions (Figure 7). All

sera, except mouse and sheep, lysed the sensitised vector control cells readily, averaging 80% lysis at a 1/10 dilution. Mouse and sheep sera gave a maximal lysis of 56% and 67% respectively at a dilution of 1/10. Expressed human
5 CD59 markedly inhibited lysis by human, pig and sheep complement, but only moderately inhibited lysis by rodent complement. Expressed pig CD59 showed a pattern of protection almost identical to that of human CD59 for all species tested. In particular, pig CD59 and human CD59,
10 expressed at similar levels in the same cell type, were equally effective at inhibiting lysis by human complement. The anti-pig CD59 mAb MEL-1 blocks function of this molecule. Preincubation of pig CD59-expressing cells with this antibody effectively eliminated the protective effect,
15 confirming that inhibition was due to the expressed pig CD59 (Figure 7).

Example 5: Hyper-expression of pig CD59 in pig endothelial cells and cell lines

Pig CD59 was hyper-expressed in the pig endothelial
20 cell line PLECT and in pig kidneys and testis cell lines essentially as described in Example 3. For comparison Human CD59 was hyper-expressed in the same lines. The extent of hyper-expression was typically 4 - 10-fold in comparison with endogenous expression on PLECT cells as assessed by
25 flow cytometry. The human complement lytic sensitivity of the PLECT cells was measured and the results shown in Figure

8. PLECT cells hyper-expressing pig CD59 are protected from lysis by human complement at least as well as PLECT cells expressing human CD59. These studies indicate that hyper-expression of a pig CRP in pig endothelium provides
5 protection against damage by human complement which is at least as great as that conferred by hyper-expression of the equivalent human CRP. Similar results were obtained with the other porcine cell lines.

Example 6: Comparison of Pig MCP and Human sMCP

10 500ng of human C3 was incubated for various times at 37°C with 50ng of human factor I and 50ng pig MCP or human sMCP. The time course of cofactor activity was observed by Western blotting, probed with anti-human C3C, and the results shown in Figure 9.

15 500ng of human C3 was incubated with 50ng of human factor I and various amounts of pig MCP or human sMCP for 16 hours at 37°C. A Western blot of reduced samples was probed with anti-human C3c, and the results shown in Figure 10. From this it will again be seen that pig MCP is a better
20 cofactor than Human sMCP for cleavage of human C3 by human factor I.

Rabbit erythrocytes were incubated in the presence of human sMCP or pig MCP under classical or alternative pathway conditions to monitor the relative effectiveness of human
25 sMCP and pig MCP as inhibitors of haemolysis by human serum. The results are shown in Figure 11 from which it will be seen that pig MCP is a better regulator of the classical

pathway of human complement than human sMCP and that pig MCP and human sMCP have similar activity in regulation of the human alternative pathway.

Example 7: Pig DAF

5 We have purified, using a mixture of classical and affinity methods, pig DAF from erythrocyte membranes and undertaken a partial characterisation of the purified protein. Referring to Figure 12, pig DAF has been isolated from pig erythrocyte membranes by butanol extraction and
10 passage of the butanol extract over a column of a weakly cross-reactive anti-human DAF monoclonal antibody (MBC-1) coupled to sepharose. The bound protein was eluted with 50mM diethylamine, dialysed against PBS/Chaps and concentrated in an ultrafiltration cell. The protein has a
15 molecular weight of approximately 65kDa on SDS-PAGE gels, is GPI-anchored and spontaneously incorporates into the membrane of target erythrocytes. Incorporation of pig DAF into guinea pig erythrocytes conferred protection against lysis by pig serum whether activated through the classical
20 or alternative pathways (Figure 13). Incorporation into erythrocytes bearing C5b-7 sites failed to confer protection against lysis by C8/C9, confirming that the incorporated protein inhibited in the activation pathways (negative data not included). Initial tests on the species selectivity of
25 pig DAF indicate that it readily inhibits human complement.

Amino-terminal sequencing was obtained through the first 14 residues, 12 of which were identified with

confidence. The sequence (DCGLPPxVPxAQPA) was highly homologous with the amino terminal sequence of human DAF. Partial cDNA sequence has been obtained using a PCR-based approach with a primer designed from the above sequence and from internal protein sequences predicted from comparisons of DAF sequences in human, mouse, rat (our original data) and guinea pig to be highly conserved. The cDNAs so obtained have been labelled and used as probes to isolate full-length pig DAF cDNA clones from a pig testis cDNA library.

Clones encoding pig DAF have been isolated from this pig testis cDNA library using these probes.

Sequencing of clones has provided several cDNA sequences, all identical through the 3' region (encoding the signal peptide and the first three short consensus repeats (SCRs) of pig DAF) but thereafter, diverging. For examples, see clones pDAF-14 and pDAF-7 cDNA sequences (Figure 14).

The predicted protein sequence of pig DAF through the first three SCRs is approximately 60% identical to the human DAF sequence (Figure 15). Clone pDAF-7 contains, after these SCRs, a Ser/Thr/Pro-rich (STP) region homologous with the human STP-A and a carboxy-terminal sequence which may encode a glycolipid anchor but is also homologous with the membrane anchoring sequence in the transmembrane form of mouse DAF (Figure 15).

Northern blotting of RNA extracted from pig tissues using a cDNA probe derived from the pig DAF sequence given in Figure 14 identifies at least five specific bands in the

majority of tissues (Figure 16), indicating that multiple forms of the message exist. It is anticipated that forms of pig DAF containing a fourth SCR and/or glycolipid anchoring sequences, analogous to those in human DAF, will be found upon sequencing these other mRNAs.

The first three SCRs of pig DAF have been expressed as an Fc fusion protein in CHO (Chinese Hamster Ovary) cells. The recombinant protein, purified on protein A sepharose, has been used to immunise experimental animals for the purpose of producing specific antibodies. Preliminary functional analysis of the recombinant pig DAF-Fc reveals excellent complement inhibitory activity in classical pathway assays for both pig and human serum (Figure 17).

A probe derived from the cDNA sequence given in Figure 14 has been used in a radiation hybrid system to localise the gene for pig DAF to the long arm of chromosome 9.

EXAMPLE 8

Induced protection in PAEC following non-lethal complement attack

A propidium iodide uptake assay was used to monitor lysis of PAEC by human serum. PAEC were harvested from tissue culture flasks by incubation in PBS/1mM EDTA and gentle scraping, washed in the complement-fixation diluent (CFD; Oxoid) and resuspended in CFD at 10^6 /ml. Portions were incubated with various dilutions (in CFD) of human serum (containing natural antibody) for the periods stated. The cells were then chilled to 4°C and propidium iodide (PI)

added (from a stock at 1mg/ml in DMSO) to a final concentration of 10 μ g/ml. Cells were analysed within 30 minutes by running on the flow cytometer, measuring fluorescence in the red channel (FL2). PI-positive (lysed) cells were highly fluorescent and easily distinguished from unlysed cells. The percentage of total cells in the highly fluorescent population was taken as percent lysis. Each set of conditions was run in triplicate.

Thus, PAEC (primary pig aortic endothelial cells) were incubated for one hour at 37°C with concentrations of human serum (containing natural antibody) which did not cause significant amounts of lysis of the cells (1/20, 1/30, 1/40; lysis always less than 10%). Control cells were subjected to a similar incubation but in the absence of serum. The cells were then washed and incubated for further 1 hour at 37° with various concentrations of serum in the range 1/2 to 1/256. Cell killing was measured by propidium iodide uptake. PAEC exposed to non-lethal complement attack at each of the three doses were much more resistant to lysis than unattacked control cells (Figure 19a). Specific lysis was reduced to less than 20% of that in controls following non-lethal attack using serum at 1/20.

Flow cytometry was also used to measure expression of CD59 and MCP on PAEC, unattacked or attacked non-lethally with human serum. Cells were chilled to 4°C, washed once in cold FACS buffer (PBS containing 1% bovine albumin and 0.1% sodium azide), incubated with primary antibody (monoclonal anti-pig CD59 or anti-MCP, detailed earlier) at 10 μ g/ml in

FACS buffer for 1 hour at 4°C, washed twice in FACS buffer, incubated with secondary antibody (FITC-labelled anti-mouse IgG diluted 1:100 in FACS buffer) for 1 hour at 4°C, washed and resuspended in cold FACS buffer and analysed on the flow cytometer, measuring fluorescence in the green channel (FL1). The median fluorescence was taken as a measure of expression. All samples were run using identical machine settings. No significant change in expression of CD59 or MCP was detected following non-lethal complement attack and binding of human immunoglobulin was similarly unaffected (Figure 19b).

These data support the concept that porcine endothelium can be rendered resistant to complement by first exposing to a non-lethal attack with complement. The resistant state is relatively long-lived (hours to days). The resistance observed was not accompanied by an increase in expression of CD59 or MCP.

EXAMPLE 9

Induced protection in PAEC following a period of anoxic stress

The appropriate gas mixture was prepared in 50ml graduated syringes by first "drawing up" 47.5ml N₂ from a cylinder of O₂-free N₂ and then "drawing up" a further 2.5ml of air (all through a 0.2μM filter). Small flasks containing PAEC (total volume 25ml) were carefully filled from bottom up with the gas mixture and sealed. Following

incubation for various intervals, cells were harvested, susceptibility to complement lysis was assessed by PI exclusion as described in Example 8 and expression of CD59 and MCP by flow cytometry as described in Example 8.

5 Thus, semiconfluent flasks of PAEC, grown in standard medium and environment (37°C, 95% air and 5% CO₂ were gassed with 5% air, 95% N₂, the flasks were sealed and incubated for intervals at 37°C. Cells were harvested, a portion removed for measurement of complement regulator expression and the remainder incubated with various amounts of human serum in a standard lytic assay format. Cells subjected to anoxia for periods of 12, 24 and 48 hours were more resistant to lytic killing by human complement than were control cells not subjected to anoxia (Figure 20a).

10
15 Expression of CD59 and MCP and binding of human Ig were not significantly altered on PAEC subjected to anoxic stress when compared with controls (Figure 20b).

20 These data support the concept that porcine endothelium can be rendered resistant to complement by first exposing to a period of anoxic stress. The resistance observed was not accompanied by an increase in expression of CD59 or MCP.

EXAMPLE 10

Induced protection in human cell lines following growth arrest induced by nutrient deprivation or cell density

25 Lytic susceptibility of K562 cells and U937 cells was assessed by propidium iodide uptake essentially as described

in Example 8, except that a prior antibody sensitisation step (polyclonal anti-U937 antiserum, 1:10, 30 min at 4°C) was necessary to obtain complement activation.

Expression of DAF, MCP and CD59 on K562 cells and U937
5 cells were assessed by staining with appropriate monoclonal antibodies, followed by FITC-labelled secondary antibody and analysis by flow cytometry, essentially as described in Example 8.

Subconfluent flasks of the human erythroleukaemia cell
10 line K562 and the lymphoblastoid line U937 grown under standard conditions (medium containing 10% of fetal calf serum [FCS]), were subjected to nutrient deprivation by incubating in medium containing 1% FCS.

Alternatively, cells in medium containing 10% FCS were
15 allowed to reach confluence and maintained at this density, with replacement of spent medium every 24 hours. Cells from both sets of condition were harvested after various periods and complement susceptibility assessed in a standard lytic assay.

Both nutrient-deprived and confluent cells remained
20 viable for >72 hours but did not increase significantly in cell number during this period, confirming that they were growth-arrested.

Cells growth-arrested either by nutrient deprivation or
25 by reaching confluence in culture were more resistant to complement lysis than were control cells maintained in log phase in standard culture conditions (Figure 21a).

Expression of DAF and MCP were not significantly

altered on K562 cells subjected to growth arrest when compared with controls, but CD59 expression was reduced on cells growth-arrested by nutrient deprivation (Figure 21b).

These data support the concept that cells can be rendered resistant to complement by first exposing to a period of growth arrest. The resistance observed was not accompanied by an increase in expression of CD59, DAF or MCP.

EXAMPLE 11 - Induced protection of PAEC by treatment with exogenous stimuli

Medium was removed from the PAEC in semiconfluent culture, replaced with fresh medium containing the appropriate stimulus, phorbol myristate acetate at 10nM final concentration, and returned to the incubator. At various timepoints, cells were harvested and lytic susceptibility assessed by PI uptake essentially as described in Example 8.

Expression of CD59 and MCP was assessed by flow cytometry essentially as described in Example 8.

As shown by Figure 18 the PAEC became more resistant to lysis by human or pig serum. A significant increase in resistance is achieved even after one day of treatment and further increases are seen up to three days of treatment.

Concomitant with the increase in resistance, expression of MCP on the PAEC rose two-fold but CD-59 expression is

unaltered (Figure 18).

These data support the concept that porcine endothelium can be rendered resistant to complement by treatment with exogenous chemicals, in this instance PMA. The resistance observed was not accompanied by an increase in the expression of CD59 or MCP.

EXAMPLE 11 - Expression and function of pig complement regulators on porcine aortic endothelial cell

Aortic endothelial cells were harvested from fresh pig aortae and placed in culture. Expression of CD59 and MCP on primary cells and cells up to passage five was assessed by staining with specific monoclonal antibodies MEL2 and MEL3 (anti-CD59) or 4C8 and 1C5 (anti-MCP). The expression of CD59 fell steadily with increased passage number (Figure 22) whereas MCP expression increased at later passage number (Figure 23). Primary pig aortic endothelial cells (PAEC) were much more resistant to complement lysis than cells passaged in culture (Figure 24). Blocking of endogenous CD59 with a monoclonal antibody (MEL2) markedly enhanced the susceptibility of PAEC to lysis by human serum whereas blocking of endogenous MCP had no discernible effect on lytic susceptibility (Figure 25).

Incorporation of human CD59 into PAEC on which the endogenous pig CD59 had been blocked by monoclonal antibody fully restored the resistance level of the PAEC to that of cells in which endogenous CD59 had not been blocked (Figure

26).

These data provide further corroboration that CD59 is a major complement resistance factor in PAEC and that pig CD59 and human CD59 are of similar efficacy in protecting
5 against human complement lysis of PAEC.

CLAIMS

1. A graftable animal cell or tissue of a donor species for use in medicine, wherein said cell or tissue expresses, or is capable of being caused to express, increased amounts of endogenous complement regulatory molecules for preventing activation of complement in a recipient species.

2. A cell or tissue according to Claim 1, for use in transplantation therapy.

3. A cell or tissue as claimed in Claim 1 or Claim 2, wherein the tissue is an organ.

4. A cell or tissue as claimed in Claim 3, wherein the organ is a heart, lung, liver, kidney, pancreas, or thyroid.

5. A cell or tissue as claimed in Claim 1 or Claim 2, wherein the tissue is skin.

6. A cell or tissue as claimed in Claim 1 or Claim 2 comprising isolated cells selected from islet cells, neurones, and stem cells.

7. A cell or tissue as claimed in any of the preceding Claims, wherein said complement regulatory molecules comprise complement regulatory proteins (CRPs).

8. A cell or tissue according to Claim 7, wherein said CRPs comprise or have the activity of one or more, of CD59, Membrane Cofactor protein (MCP), Decay Accelerating Factor (DAF;CD55), homologous restriction factor (HRF), CR1 (CD35).

9. A cell or tissue according to any of Claims 1 to 8, wherein said donor species is a pig.

10. A cell or tissue according to any of Claims 1 to 8, wherein said donor species is a sheep.

11. A cell or tissue according to any of the preceding Claims, wherein the recipient species is human.

12. The use of an animal cell or tissue derived from a donor species, and one or more complement regulatory molecules endogenous to the donor species which can be hyper-expressed to prevent activation of complement in a recipient species, in the preparation of tissue graftable into the recipient species without hyperacute rejection.

13. A method of preparing an animal cell or tissue derived from a donor species for transplanting into a recipient species, and/or for reducing the likelihood of hyperacute rejection once transplanted, which comprises causing said cell or tissue to express increased amounts of the endogenous complement regulatory molecules sufficient to prevent complete activation of complement in the recipient species.

14. A method according to Claim 13, which comprises transfecting the cell or tissue with a viral vector encoding a complement regulatory molecule.

15. A method according to Claim 13, wherein said complement regulatory molecule is a CRP, and which comprises the use of cytokines or other factors acting directly or indirectly on regulatory elements in the CRP gene to increase expression of said CRP before, during or after

transplant.

16. A non-human transgenic animal having cells or tissue which hyper-expresses endogenous complement regulatory molecules.

5 17. A DNA molecule selected from:

(a) a pig CD59 gene or its complementary strand,

(b) a sequence substantially homologous to, or capable of hybridising to, a substantial portion of a gene defined in (a) above,

10 (c) a molecule coding for a polypeptide having the sequence of Figure 2 (SEQ ID No. 2),

(d) genomic DNA corresponding to a molecule in (a) above; and

(e) a fragment of a molecule defined in any of (a),

15 (b), (c), or (d) above, other than the fragment described SEQ ID No. 1.

18. A DNA molecule selected from:

(a) a pig DAF gene or its complementary strand;

(b) a sequence substantially homologous to, or capable of hybridising to, a substantial portion of a gene defined in (a) above;

(c) a molecule coding for a polypeptide having the sequence of Figure 15 (SEQ ID Nos. 17-19),

(d) a genomic DNA corresponding to a molecule in (a) above; or,

(e) a fragment of a molecule defined in any of (a),

(b), (c), or (d) above.

19. An RNA molecule comprising an RNA sequence corresponding to a DNA sequence according to Claim 17 or Claim 18.

20. A nucleic acid probe having a sequence according to any one of Claims 17 or 19, and optionally including a label.

21. An isolated, purified, or recombinant polypeptide comprising a pig CD59 protein or a mutant, variant or portion thereof or encoded by a sequence according to Claims 17 or 19 or a variant thereof having substantially the same activity as the pig CD59 protein.

22. A polypeptide according to Claim 21, wherein the pig CD59 protein has the amino acid sequence defined in Figure 2. (SEQ ID No. 2).

23. An isolated, purified or recombinant polypeptide comprising a pig DAF protein or a mutant, variant or portion thereof or encoded by a sequence according to Claim 18 or 19 or a variant thereof having substantially the same activity as the pig DAF protein.

24. A polypeptide according to Claim 23 wherein the pig DAF protein has the amino acid sequence defined in Figure 15 (SEQ ID Nos 17-19)

25. An anti-pig CD59 monoclonal antibody or a labelled anti-pig CD59 monoclonal antibody.

26. A vector comprising the nucleic acid sequence of any one of Claims 17 and 19.

27. A host cell transfected or transformed with a vector according to Claim 26.

28. The use of a vector according to Claim 27 or a nucleic acid sequence according to either Claim 17 or Claim 18, in gene therapy and/or in the preparation of a cell or tissue for xenotransplantation.

5 29. A non-human transgenic animal wherein the transgene comprises the DNA of Claim 17 or Claim 18.

30. Nucleic acid primers selected from the following, as herein defined:

A-Pig : C-Pig (SEQ ID No.3 : SEQ ID No.4)

10 Q₀ : Q₁ (SEQ ID No.6 : SEQ ID No.7)

Q_T (SEQ ID No. 5)

D-Pig : E-Pig (SEQ ID No.8 : SEQ ID No.9)

RT-Pig (SEQ ID No.10)

F-Pig : G-Pig (SEQ ID No.11 : SEQ ID No.12)

15 pigxP-1 : PigxP-2 (SEQ ID No.13 : SEQ ID No.14)

31. A method of increasing the resistance of an animal cell or tissue of a donor species to complement attack when transplanted into a recipient species, which comprises one or more of:-

20 (a) exposing said cell or tissue to sub-lytic complement

attack; or

(b) exposing the cell or tissue to nutrient deprivation; or

(c) applying conditions of limited anoxia to the cell or tissue; or


5 (d) exposing said cell or tissue to ionophores; or

(e) exposing said cell or tissue to exogenous chemicals,
thereby to increase the resistance of said cell or tissue to complement attack.

32. A method according to Claim 32, wherein the exogenous
10 chemical is a lectin.

33. A method according to Claim 32, wherein the exogenous chemical is a cytokine or a chemokine.

1/29

*Fig. 1*

2/29

GAAA

-4

AGACGCGCAGGCGCGGCCGCTCTCCCGACGGGAGTAGCGCTGCAGCCGGACGCAGGGTGCAGTTA
 10 20 30 40 50 60

M G S K G G F I L L W L -14
 GAATCCATAGACGGTCACG ATG GGA AGC AAA GGA GGG TTC ATT TTG CTC TGG CTC
 70 80 90 100 110 120

L S I L A V L C H L G H S L Q C Y 4
 CTG TCC ATC CTG GCT GTT CTC TGC CAC TTA GGT CAC AGC CTG CAG TGC TAT
 130 140 150 160 170

N C I N P A G S C T T A M N C S H 21
 AAC TGT ATC AAC CCA GCT GGT AGC TGC ACT ACG GCC ATG AAT TGT TCA CAT
 190 200 210 220

N Q D A C I F V E A V P P K T Y Y 38
 AAT CAG GAT GCC TGT TTC GTT GAA GCC GTG CCA CCC AAA ACT TAC TAC
 230 240 250 260 270

Q C W R F D E C N F D F I S R N L 55
 CAG TGT TGG AGG TTC GAT GAA TGC AAT TTC GAT TTC ATT TCG AGA AAC CTA
 280 290 300 310 320

A E K K L K Y N C C R K D L C N K 72
 GCG GAG AAG AAG CTG AAG TAC AAC TGC TGC CGG AAG GAC CTG TGT AAC AAG
 330 340 350 360 370

↓
 S D A T I S S G K T A L L V I L L 89
 AGT GAT GCC ACG ATT TCA TCA GGG AAA ACC GCT CTG CTG GTG ATC CTG CTG
 380 390 400 410 420

L V A T W H F C L * 98
 CTG GTA GCA ACC TGG CAC TTT TGT CTC TAA
 430 440 450

CTGTACACCAGGAGATTTCTCCTCAACTTCCTCTGTCTCTCTGTTTCTATTTCCCATGCTGCGGTGTT
 460 470 480 490 500 510 520


CCAAAGGCTGTGTATGCTCCAGCTTCTTCTCTGTTGGGAAGGACTAAACCTAGCTTGAGCACITTTGGATT
 530 540 550 560 570 580 590

AGAGAGAGAAACTTTGAGCGACTTTGAAGACCAGGCTTGTGGCAGAGAAACCTGTGAGAGGGGAAAC
 600 610 620 630 640 650 660

GTTTAAAGATGAAGCACAGGTGATTTGAGCGAGGCCATGCGTCTTCTCTGCTCTTGGCAGGACCAG
 670 680 690 700 710 720 730

CTTTCGGTAAACCATTCGATAGATTCCACAATCCTT
 740 750 760

Fig. 2

*Fig. 3*


4/29

-20 -10 1 10 20 30
 | | | | | |
 FIG: MGSKGFTLLWLLSLAVLCHLGHSLQYNCINP-AGSCTTAMNCSHNQDACIFVEAVPKTYQ
 | | | | | | | | | |
 HUM: MGIQGGSVLFGLLVLAVFCHSGHSLQYNCNP-TADCKTAVNCSSDFDACLITKAGLQVYN-K
 | | | | | | | | | |
 RAT: MRARRGFI--LLL-LAVLCSTGVSLRCYNCLDP-VSSKTNSTCSPNLDACLAVAVSGKQVYQ-Q
 | | | | | | | | | |
 MUR: MRAQRGLIL--LLLLAVFCSTAVSLTCYHCFQPVVSSCNMNSTCSPDQDSCLYAVAGMQVYQ-R


40 50 60 70 80 90
 | | | | | |
 FIG: CWRFEDECNFDNISRLAEKKLYNCCRKDLCNKSD-----ATIS-SGKTALL-VILLVATWHFCL.
 | | | | | | | | | |
 HUM: CWKFEHCNFDVTTIRLENELTYCYCKKDLCNFNEOLEN--GGTSLSEKTVLLVTPFLAAAWSLHP.
 | | | | | | | | | |
 RAT: CWRFSDCNAKEILSRLEIANVQYRCCQADLCNKSFEDKPNNGAISLLGKTALL-VTSVLAAILKPCF.
 | | | | | | | | | |
 MUR: CWKQSDCHGEIIMDQLEETKLKFRCCQFNLCKNSD-----GS-LGKTPLLGTSVLVAAIL-NLCFLSHL.

Fig. 4

5/29





**Fig. 5**

6/29

*Fig. 6*

7/29

Fig. 7 (part 1 of 2)



8/29






Fig. 7 (part 2 of 2)

9/29



Time course Cofactor activity: pig MCP vs Hu sMCP

Fig. 9




500 ng C3 was incubated with 50 ng factor I and 50 ng pig MCP or human sMCP

Pig MCP is a better cofactor than Hu sMCP for human C3 and human factor I

11/29

Dose/response Cofactor activity: pig MCP vs Hu sMCP

300 100 30 10 3 1 - 300 100 30 10 3 1 - ng MCP



— Pig MCP — — Hu sMCP —


500 ng C3 was incubated with 50 ng factor I and various amounts of pig MCP or human sMCP for 16 at 37°C. W.blot of reduced samples, probed with anti Hu C3c

Pig MCP is a better cofactor than Hu sMCP for human C3 and human factor I


12/29

Fig. 11

Inhibition of CP and AP of human serum
by human sMCP and pig MCP




RaE were incubated with human serum in the
presence of Hu soluble MCP or pig MCP under CP
or AP conditions.




Pig MCP is a better regulator of the CP of
human C than human sMCP.
Pig MCP and Hu sMCP have similar activity in
regulation of the human AP.

13/29

*Fig. 12*

14/29

**Fig. 13**

15/29

pDAF-7 cDNA sequence:

CCACC CGCGTGGCGGCNCGCTCTAGAAC TAGTGGATCCCCCGGGCTGCAG
 GAATTCGGCAGCAGATTTCGCTCTAATCGCGGAGGTCGACAGATCCGGGA
 GCCGCTCGGGGTCCCGTTCGCCGCGCCATGAGTCCCTGCCGCGGAGC
 GCCCCGCGGTGAGGCGCCTAATGGGCGGACAGACGCCGCCGCCCTGCT
 GCTGCTGCTGCTGCTGCTGTGTATCCCGGCTGCGCAGGGTGACTGCAGCC
 TCCACCCGATGTACCTAATGCCCAACAGATTTGCGAGGCTTGCAAGT
 TTTCTGAACAAACCACATAACATACAAATGTAAACAAGGCTTTGTCAA
 AGTTCTTGGCATGCGAGACTCAGTGCTGTCTGTCTAATGATAAATGGTCAG
 AAGTTCAGAAATTTTGTAACTGTAAGTGTGATGTTCCAAACCGGTACAT
 TTTGCATCTCTTAAAAAGTCTTACAGCAACAGAAATATTTCACAGAGGG
 TTTCAACCGTGAATATGAGTGGCGTAAAGGCTATAAAAGGATCTTACTC
 TATCAGAAAACTAATTTGCCCTCAGAAATTTACGTGGTCCAAACCTGAT
 GAATTTTGCAAAAAAACAAATGTCGACTCCTGGAGAACTAAAAAATGG
 TCATGTCAATATAACAACAGTCTGTTATTGGCGCATCCATCTTTTCT
 CATGTAAACGAGGGTACAGACTAGTTGGTGGCACTTCAGTACTGTTT
 GCCATAGCAATGATGTTGAGTGGAGTGATCCATTGCCAGATGGCAAGA
 AATTTCTCAACTGTCAAAGCCATACAGCTGTTGAGAAACCCATCACAG
 TAAATTTCCAGCAACAAGATCCAGCTATTCCAGGGCCACAACGAGT
 TTTCAATCAAGTACATCTAAAAATCAGGAGAACCCCTTCTCAGCATGAG
 AATCATGTGCTGGTACCATGCTACTTATGCAAGGAGTGTGCTGTTA
 TTATAATAATTTGTTGCCCTAATCTAGCCAAAGGTTTCTGCACTATGGA
 AAATCAGGCTCTTACCACTCATGAGAACAAACAGCCGTTAATGTTGC
 ATTTTATAATTTACCTGCGACTGGCATGCCGAGTGTGAGAACCCATCAG
 ATTAACAAAAGGAGCTGATGTGTAACACTGACAGTTTGGCTTATGGTGC
 TAGTAACCATTTGGCTAGCTGACTTAGCCAAAGAGTGAAGAAGAAAGT
 GCACACAAGTACACAGAAATTTTCAGTTTCTTAAACCTTTCAGGTGGGA
 GTGGACATAGTTTGTGGTAGTGTCTTCGNTTGGCATGGTTTCAATGGCT
 CTAAGGNACATAGGAATGCACAGAACNAAGAGAAACAAATCTATCTGA
 AANTACATCTCAACACTTCTAANACTTTGGAAATNGAACAGNTCATTA
 AGATTTGGGAGCAATTACTTTCCCAAAAAGGGTGAGAAAAATGGAGAAATTT
 GGTCATGGGTAGNAATTTNGAAAAAAGAAACCCNAAGGGGANTTTTCC
 CCCCCAAAGGGGNAAGGGTATTTTATTTAATTAAGGNAAAAAA
 AAAAAACCCNNNGGGGGGCCCGGNCCTATTTCCCT

pDAF-14 cDNA sequence:

CACGAGCCGCCGCCGCTGCTGCTGCTGCTGCTGCTGTGTATCCCGGC
 TCGCAGGGTGACTGCAGCCTTCCACCCGATGACCTAATGCCCAACAG
 ATTTGCGAGGCTTGCAGTCTTCTGGAACAACCAATAACATACAAA
 TGTAAACAAGGCTTTGTCAAAGTTCCTGGCATGGCAGACTCAGTGCCTG
 TCTTAATGATAAATGGTCAGAAGTTCAGAAATTTGTAATCGTAGCTGTG
 ATGTTCCAACCAAGCTACATTTTGCATCTCTTAAAAAGTCTTACAGCAAA
 CAGAATATTTCACAGAGGGTTTCCAGTGGAATATGAGTGGCGTAAAGG
 CTATAAAAGGATCTTACTCTATCAGAAAAAACAATCTGCTTCAGAAAT
 TTACGTGGTCCAAACCTGATGAATTTGCAAAAAAACAATGTCCGACT
 CTGGAGAACTAAAAAATGGTCAATGTAATAACAACAGCTGCTGTTATT
 TGGCGCATCCATCTTTTCTCATGTAAACGAGGGTACAGACTAGTTGGTG
 CAACCTTCAGTACTGCTTTTGGCCATAGCAAAATGATGTTGAGTGGAGTAT
 CCATTGCGAGAGTGCAGAAATTTCTCCAAGTGTCAAAGCCATACCAGC
 GTTGAGAAACCCATCACAGTAAATTTCCAGGTACCAAGCCCTATCAT
 CTCTCAGAAACCTCCACAGCAAACTACTAGCTACAGAGTTACTACCA
 ACTCTCAGGAACCCACCAAGTAAATGTTCCAGATAGTAAGCCATATC
 ATCTCTCAGAAACCTCCACAGTAAATCTCCAGTACAGACTTACTAC
 CAACTCTCAGGAACCCACCAAGTAAATGTTCCAGATAGTAAGCCATA
 TCATCTTCTCAGAAACCTCCACAGTAAATCTCCAGTACAGTACTACTA
 CCAACTCTCAGGAACCCACCAAGTAAATG

Fig. 14

16/29

pDAF-7, predicted protein sequence:

HGGQTTPPLLLLLLLCLIPAAQGDCLPPDPVNAQDPLRGLASFPEQTTI
 TYKCNKGFVKVPGHADSVLCLNDKWSEVAEFCNRSCDVPTRLHFASLKKS
 YSKONYFPEGFTVEYECRKGKRDLTSEKLTCLQNFWSKPODFCKKKQ
 CPTPGELKNGHVNIITDOLLFGASIFFSCNAGYRLVGATSSYCFAIANDVE
 WSDPLPDCQEIISPTYKAIPAVEKPIITVNFPAATKYPAIPRATTSFHSSTSK
 NRGNPSSGMRIMSSGTMLLIAGGVAVIIIIIVALILAKGFWHYKSGSYHT
 HENNKAVNVAFYNLPATGDAADVPRGN.

pDAF-14, predicted protein sequence:


HEPPPLLLLLLLCLIPAAQGDCLPPDPVNAQDPLRGLASFPEQTTI
 TYKCNKGFVKVPGHADSVLCLNDKWSEVAEFCNRSCDVPTRLHFASLKKS
 YSKONYFPEGFTVEYECRKGKRDLTSEKLTCLQNFWSKPODFCKKKQ
 CPTPGELKNGHVNIITDOLLFGASIFFSCNAGYRLVGATSSYCFAIANDVE
 WSDPLPDCQEIISPTYKAIPAVEKPIITVNFPAATKYPAIPRATTSFHSSTSK
 LLPTPQEPITVNPDSKAISSPOKPSVTYNTPATDLLPTQEPITVNPDS
 KAIISSQKPSVTYNTPATIYQLLRNPPQ.

Alignment with human DAF (conserved residues marked as *):

1	10	20	30	40	50	
PSVPAALPLL	GELPRL	LLLVLL	CLPAV	WGDCGL	PPDPVNAQ	PALEGR
						HuDAF
MGGQTTP	-----	PLLLLLLL	CLIPAAQGDCL	PPDPVNAQDPLRGLAS	pDAF-7	
51	60	70	80	90	100	
FPEDTVIT	YKCEESFVK	IPGEKDSV	TCLKGOWSD	IEEFCNR	SCDVPTRL	HuDAF
						pDAF-7
FPEOTTIT	TYKCNKGFVKVPGHADSVLCLND	-KWSEVAEFCNRSCDVPTRL				pDAF-7
101	110	120	130	140	150	
NSASLKOPYI	TQNYFPV	GTVEYECR	PGYRREPS	LSPKLTCL	QNLKWSTA	HuDAF
						pDAF-7
HFASLKKS	YSKONYFPEGFTVEYECRKGKRDLTSEKLTCLQNF	WSKP				pDAF-7
151	160	170	180	190	200	
VEFCCKKSC	PNPGEIRNGQ	IDVPGGIL	FGATISF	SCNTGYKL	FGSTSSFC	HuDAF
						pDAF-7
DEFCKKQ	CPTPGELKNGHVNIITDOLLFGASIFFSCNAGYRLVGATSSYC					pDAF-7
201	210	220	230	240	250	
LISGSSVQW	SDPLPECREI	YCPAPPQIDNGI	IOGERDHYG	YRQSYTYACN		HuDAF
						pDAF-7
FAIANDVE	WSDPLPDCQEI	-----				pDAF-7
						↑end SCR3
251						
KGFTIHGEHSI	YCTVNNDEGEW	SGPPPECRG	SKLTSKYPTV	QKPTTVNV		HuDAF
						pDAF-7
						-----SPTYKAIPAVEKPIITVNF
						↑end SCR4
301						
PTTESVPTS	QKTTTKTTTP	NAQTRSTPYS	RTIKHFETTP	NKSGGTTSG		HuDAF
						pDAF-7
PATKYPAI	PRATTSFHSSTSK	NRGNPSSGMRIM	SSGTMLLIAGGVAVIIII			pDAF-7
						↑end STP-A
351						
TTRLLSGHT	CTLTGLGLTV	TMGLLT				HuDAF
						pDAF-7
						IVALILAKGFWHYKSGSYHTHENNKAVNVAFYNLPATGDAADVPRGN.

Fig. 15


17/29



Northern analysis of porcine DAF

Fig. 16


18/29



Antibody-sensitised human erythrocytes in GVB were incubated for 30 min at 37°C with various dilutions of pig or human serum in the presence or absence of pig DAF-Fc at 10 µg/ml (final). Haemolysis was measured by quantifying haemoglobin release into supernatant.

Fig. 17a Activity of pig DAF-Fc

19/29



Antibody-sensitised human erythrocytes in GVB were incubated for 30 min at 37°C with a constant dilution of human or pig serum (1:20) and various amounts of pig DAF-Fc (0 - 50 µg/ml (final)). Haemolysis was measured by quantifying haemoglobin release into supernatant.


Fig. 17b Activity of pig DAF-Fc - dose response with human and pig serum


20/29

Effect of PMA on expression of CD59 and MCP and C-susceptibility of PAEC


Fig. 18

PAEC were cultured in the presence of 10 nM PMA. Cells were harvested and analysed for expression of pig CD59 and pig MCP and other cell surface markers and susceptibility to lysis by NHS






Effect Of Non-Lethal Complement Attack on the Lysis Of PAE cells PAE cells were incubated with 1/20 (▲), 1/30 (▼), 1/40 (●) or zero human serum (■) before being used in a propidium iodide cell killing assay against NHS. Values are means of triplicates \pm SD.




Staining of NCA Treated PAE Cells Sensitised PAE cells were incubated with different non-lethal concentrations of human serum. These cells were then stained for MCP (■), Human IgG (●), CD59 (▲), P-selectin (total cells) (□) or P-selectin (positive staining cells) (▼). Values are means of triplicates \pm SD.

22/29

Fig. 20a Effects of anoxia


PAEC were incubated under anoxic conditions at 37°C for 0, 12 or 48 hours. Cells were then subjected to complement attack by exposing to various dilutions of human serum

23/29

Fig. 20b Effects of anoxia


PAEC were incubated under anoxic conditions at 37° C for 0, 12 24 or 48 hours. Cells were then analysed by flow cytometry for expression of CD59, MCP or binding of Hulg.

24/29



a: K562 cells were growth-arrested either by nutrient deprivation (triangles) or by maintaining at confluence in culture (squares). Control cells (circles) had been maintained in log growth in normal medium. Cells were then antibody sensitised and exposed to various dilutions of human serum. End-point lysis was measured at 60 min.


b: Cells growth arrest as above were stained for the various complement inhibitors and analysed on the FACScan. Open bar; control; hatched bar; confluence; solid bar; nutrient deprived. All points are mean \pm SD of triplicates.

Fig. 21a**Fig. 21b**

25/29**Expression of pig CD59 on pig aortic endothelial cells (PAEC) at different passages.**

Cells were harvested from pig aortae and cultured. Cells were stained for pig CD59 using mAb's Mel2 and Mel3. after 1 day culturing (Primary) or after subculturing (P1-P5, appr. 4-7 days between passages).

CD59

**Fig. 22**

26/29

**Expression of pig MCP on pig
aortic endothelial cells (PAEC) at
different passages.**

Cells were harvested from pig aortae and cultured. Cells were stained for pig CD59 using mAb's 4C8 and 1C5. after 1 day culturing (Primary) or after subculturing (P1-P5, appr. 7 days between passages).




Fig. 23

27/29

C-susceptibility of pig aortic endothelial cells (PAEC) at different passages.

Cells were harvested from pig aortae and cultured. Cells assayed for C-susceptibility, after 1 day culturing (primary) or after subculturing (P2 and P5). The cells were also analysed for the expression of CD59, MCP and binding of human Ig





Fig. 24

28/29

Effect of blocking CD59 and MCP of C-susceptibility of PAEC.

PAEC were incubated with blocking Ab's against CD59 and MCP and C-susceptibility was assessed after challenging with HuS




Fig. 25

29/29

Incorporation of Human CD59 into PAEC and effect of blocking of human and pig CD59 on C- susceptibility.

PAEC were incubated with 1 μ g/ml CD59 for 30 min and followed by incubation with blocking antibodies against Human CD59 (Bric229) and pig CD59 (Mel2). Cells were assayed for C-susceptibility and levels of pig and human CD59




Fig. 26

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

the specification of which: *(check one)*

REGULAR OR DESIGN APPLICATION

☐ is attached hereto.

☐ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

☒ was described and claimed in International application No.

PCT/GB99/01085 filed on **8th April 1999** and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
GB	9807520.3	9th April 1998	Yes

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status—patented, pending, abandoned)

POWER OF ATTORNEY

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from WYNNE-JONES, LAINE & JAMES as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoit CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, Thomas W. PERKINS, Reg. No. 33,027, and Roland E. LONG, Jr., Reg. No. 41,949, c/o YOUNG & THOMPSON, Second Floor, 745 South 23rd Street, Arlington, Virginia 22202.

Address all telephone calls to Young & Thompson at 703/521-2297.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Bryan Paul MORGAN
(given name, family name)

Inventor's signature B.P. Morgan Date 27.9.00

Residence: Cardiff, UK GBX Citizenship: UK

Post Office Address: University of Wales College of Medicine
Heath Park
Cardiff
CF14 1XN
United Kingdom

Full name of second joint inventor, if any: Neil Kevin RUSHMERE
(given name, family name)

Inventor's signature Neil K. Rushmere Date 28-9-00

Residence: Cardiff, UK GBX Citizenship: UK

Post Office Address: University of Wales College of Medicine
Heath Park
Cardiff
CF14 1XN
United Kingdom

Full name of third joint inventor, if any: Stewart James HINCHLIFFE
(given name, family name)

Inventor's signature Stewart James Hinchliffe Date 11-10-00

Residence: Cardiff, UK GBX Citizenship: UK

Post Office Address: University of Wales College of Medicine
Heath Park
Cardiff
CF14 1XN
United Kingdom

4-60
Full name of fourth inventor, if any: Carmen Wilma VAN DEN BERG
(given name, family name)

Inventor's signature Carmen Wilma VAN DEN BERG Date 05-10-00

Residence: Cardiff, UK GB Citizenship: Netherlands

Post Office Address: **University of Wales College of Medicine**
Heath Park
Cardiff
CF14 1XN
United Kingdom